🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

BRIEF-Bellus Health and the NEOMED Institute announce agreement for development of treatment for chronic cough

Published 2017-02-28, 11:13 a/m
© Reuters.  BRIEF-Bellus Health and the NEOMED Institute announce agreement for development of treatment for chronic cough
BLU
-

Feb 28 (Reuters) - Bellus Health Inc BLU.TO

* Bellus Health and the NEOMED Institute announce an exclusive worldwide license agreement for the development of a treatment for chronic cough

* Under terms of agreement, Bellus Health will pay neomed an upfront fee of cad $3.2 million

* Upfront fee consists of CAD $1.7 million in cash and CAD $1.5 million with 5.8 million bellus health common shares

* As per agreement, NEOMED will be entitled to receive a royalty on net sales-based revenues Source text for Eikon: ID:nCNW93VmYa Further company coverage: BLU.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.